Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Baird Medical Investment Holdings (BDMD) Cash & Equivalents (2023 - 2025)

Baird Medical Investment Holdings has reported Cash & Equivalents over the past 3 years, most recently at $387496.0 for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 86.95% year-over-year to $387496.0; the TTM value through Dec 2025 reached $387496.0, down 86.95%, while the annual FY2025 figure was $387496.0, 86.95% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $387496.0 at Baird Medical Investment Holdings, down from $3.0 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $3.0 million in Q4 2024 and troughed at $387496.0 in Q4 2025.
  • A 3-year average of $1.9 million and a median of $1.5 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: surged 96.64% in 2024 and later tumbled 86.95% in 2025.
  • Year by year, Cash & Equivalents stood at $1.5 million in 2023, then surged by 96.64% to $3.0 million in 2024, then tumbled by 86.95% to $387496.0 in 2025.
  • Business Quant data shows Cash & Equivalents for BDMD at $387496.0 in Q4 2025, $3.0 million in Q2 2025, and $3.0 million in Q4 2024.